Liquid Biotech USA is a biotechnology company with a unique and powerful approach to diagnosing cancer; our technology can detect cancer at early stages of the disease.

 

Senior Management

Yasunari Kashihara, M.Sc., M.B.A.

Yasunari Kashihara, M.Sc., M.B.A.

Interim President, CEO

Yasunari (Yas) Kashihara has more than 25 years of experience in the Japanese pharmaceutical industry as Vice President, Business Development, Oncolys BioPharma Inc. and President, Oncolys USA Inc.

He joined Oncolys BioPharma Inc. in 2007 and has been responsible for the business development and corporate planning. He led the company’s historical licensing deal with Bristol-Myers Squibb in 2010 on its HIV compound with total deal size of $286 million. Before joining Oncolys, Mr. Kashihara was a President and CEO of UMN Pharma Inc. and successfully managed the rapid growth of its business during the starting up period. He especially involved fund raising of more than $30 million and successfully initiated collaboration with Protein Sciences Corporation in Connecticut. Prior to that, he was a manager of licensing at Santen Pharmaceutical Co., Ltd., after serving as a pharmacological researcher at Ciba-Geigy Japan Limited (Novartis Pharma K.K.).

Mr. Kashihara received his B.Sc. and M.Sc. degree from Kyoto Pharmaceutical University and M.B.A. degree from Trinity College Dublin in Republic of Ireland.

Co-Founders

Jay F. Dorsey, MD, PhD

Jay F. Dorsey, MD, PhD

Co-Founder, Assistant Professor, University of Pennsylvania

Jay F. Dorsey, MD, PhD is a co-Founder of Liquid Biotech USA. He is currently an Assistant Professor of Radiation Oncology at the University of Pennsylvania and an NIH R01-funded Physician-Scientist with an active translational research laboratory focused on circulating tumor biomarkers and development of novel anti-cancer therapies and theranostic agents. He is a practicing Radiation Oncologist with clinical expertise in CNS malignancies and stereotactic radiosurgery. Dr. Dorsey graduated from University of Florida, Gainesville, Florida, with a B.S. degree in Chemical Engineering and received a M.S. in Chemical Engineering from the University of South Florida (USF), Tampa, FL. He completed an M.D. and Ph.D. from USF and conducted his dissertation research in cancer signal transduction at the Moffitt Cancer Center’s Molecular Oncology Program, where he was part of one of the first research groups to characterize dual Src/Bcr-Abl tyrosine kinase inhibitors as effective against Chronic Myelogenous Leukemia (CML), which ultimately led to the development of 2nd generation CML drugs such as Dasatinib and Nilotinib (effective against imatinib-resistant CML). He completed an American Board of Radiology (ABR)-sponsored research pathway residency in Radiation Oncology at the Hospital of the University of Pennsylvania and the Abramson Cancer Center and is a board-certified Radiation Oncologist. He was an ASCO Young Investigator Awardee, recipient of a Burroughs Wellcome Fund Career Award for Medical Scientists (CAMS), and an NIH-sponsored K08 Career Award. Dr. Dorsey has expertise in the areas of CTCs, nanoparticle theranostics, radiation biology, drug discovery, molecular oncology, experimental therapeutics, and early phase clinical trials.”

Dr. Stephen M. Hahn

Dr. Stephen M. Hahn

Co-Founder, Professor, Radiation Oncology Division Head and Department Chair, Division of Radiation Oncology, MD Anderson Cancer Center

Dr. Stephen M. Hahn is an international leader in the field of Radiation Oncology. Dr. Hahn is triple-Board Certified (Radiation Oncology, Medical Oncology and Internal Medicine) and especially renowned for his expertise in lung cancer and sarcoma. A physician-scientist with a long history of successfully attracting NIH funding, Dr. Hahn’s research focuses on proton therapy, the molecular aspects of the tumor microenvironment, aberrant cell signaling in cancer cells, and tumor biomarkers. Dr. Hahn is a member of the board of directors for the American Society for Radiation Oncology, which also designated him a Fellow in 2013. In addition, he serves as a trustee for the American Board of Radiology. He is course director for the Flims Course for Clinical Trials Methodology, an educational program sponsored by various international cancer organizations that introduces junior clinical oncologists to the principles of good clinical trial design. He also is a faculty member in the Vail Course for Clinical Trials Methodology, sponsored by the American Association for Cancer Research and the American Society of Clinical Oncology. He has published over 170 scientific manuscripts.

Dr. Hahn earned his undergraduate degree from Rice University and his M.D. from Temple University in Philadelphia. He completed an internship and residency at the University of California Medical Centers-San Francisco, and a medical oncology fellowship and radiation oncology residency at the National Cancer Institute. He was previously the Henry K. Pancoast Professor and Chair of Radiation Oncology at the University of Pennsylvania where he established and led a state-of-the-art proton therapy center, increased NIH-funded research and clinical trials at the institution, and served in important university leadership roles. Dr. Hahn is now Professor and Department Chair, Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, TX, where he also leads the Division of Radiation Oncology as Division Head.

Gary D. Kao, MD, PhD

Gary D. Kao, MD, PhD

Co-Founder, Associate Professor, University of Pennsylvania

Gary D. Kao, MD, PhD is a co-Founder of Liquid Biotech USA. He is currently an Associate Professor of Radiation Oncology at the University of Pennsylvania, and a tenured Physician-Scientist dedicated towards making discoveries that lead to the most effective and least harmful treatment to the greatest number of cancer patients. Dr. Kao draws upon a skill-set crafted during the course of a twenty-year career as a Board-certified Radiation Oncologist and independent investigator on numerous private and NIH-funded grants building and leading translational research teams to pursue cutting edge problems. Dr. Kao graduated from Johns Hopkins University, with a B.A. degree in Philosophy, followed by the earning of a M.D. from Johns Hopkins School of Medicine. He completed residency training in Radiation Oncology at the Hospital of the University of Pennsylvania, earned board-certification by the American Board of Radiology (ABR), followed by a Ph.D. at the University of Pennsylvania. Dr. Kao has built the foundation for the proposed research by establishing close clinical and laboratory collaborations and developing expertise in techniques for dissecting cancer and cell biology and genetics.

Board of Directors

Yasunari Kashihara, M.Sc., M.B.A.

Yasunari Kashihara, M.Sc., M.B.A.

Board Member

Yasunari (Yas) Kashihara has more than 25 years of experience in the Japanese pharmaceutical industry as Vice President, Business Development, Oncolys BioPharma Inc. and President, Oncolys USA Inc.

He joined Oncolys BioPharma Inc. in 2007 and has been responsible for the business development and corporate planning. He led the company’s historical licensing deal with Bristol-Myers Squibb in 2010 on its HIV compound with total deal size of $286 million. Before joining Oncolys, Mr. Kashihara was a President and CEO of UMN Pharma Inc. and successfully managed the rapid growth of its business during the starting up period. He especially involved fund raising of more than $30 million and successfully initiated collaboration with Protein Sciences Corporation in Connecticut. Prior to that, he was a manager of licensing at Santen Pharmaceutical Co., Ltd., after serving as a pharmacological researcher at Ciba-Geigy Japan Limited (Novartis Pharma K.K.).

Mr. Kashihara received his B.Sc. and M.Sc. degree from Kyoto Pharmaceutical University and M.B.A. degree from Trinity College Dublin in Republic of Ireland.

Mike Dishowitz

Mike Dishowitz

Board Member

Dr. Dishowitz manages a portfolio of PCI Ventures startup companies, focusing on the medical device, biotechnology, and therapeutic sectors. His primary responsibility is to build businesses that commercialize Penn intellectual property by recruiting management, developing business strategies, fundraising, supporting company operations, and executing deals. He is also the director of Penn’s medical device startup accelerator, DevelUPmed, and manages several capital acquisition and business development programs.

Prior to joining PCI Ventures, Mike was a member of PriceSpective, a boutique consulting agency, where he specialized in determining asset valuation and pricing & market access potential of emerging life science technologies. Before entering industry, Mike spent several years in academia, studying the impact of cell signaling pathways on orthopaedic tissue and repair. He is also co-founder of a startup company based on his thesis research that uses a combination drug-device to promote bone formation and regeneration.

Mike graduated with a B.S. in Mathematics from the University of Florida and a Ph.D. in Bioengineering from the University of Pennsylvania.